Markets
929%

SoundHound now up nearly 1,000% in 2024

This is getting kind of nuts.

Matt Phillips
12/18/24 3:09PM

Voice AI company SoundHound AI surged again on Wednesday, the latest escalation in what appears to be a running battle between online cheerleaders for the stock and those betting that the run-up in the money-losing small-cap packaged-software firm must eventually bend to financial reality.

But the stock surge Wednesday — more than 20% at last glance — pushed the price past a remarkable milestone. Shareholders are now sitting close to a milestone of 1,000% gains in 2024. (It briefly hit that level in intraday trading before a somewhat hawkish rate cut from the Fed at 2 p.m.)

Over at the Reddit sub where SoundHound partisans gather, there are good feelings all around, as you might imagine, with one commenter claiming that their holding in the stock hit $1 million on today’s rally.

The current upsurge in the shares seemed to gather steam after a post over on WallStreetBets, in which a commenter laid out a pretty bearish case on the company and said they were shorting the stock, i.e. betting the shares would fall.

The argument largely centers on SoundHound’s August acquisition of enterprise-software company Amelia, which, the writer argues, is “a much shittier business than Soundhound, but it’s also ~2x its size from a financial perspective.”

“Soundhound’s financials will now be driven by the results of Amelia, and so too will the stock price,” they wrote in a post titled, “Here’s why I’m shorting Soundhound.”

On a strict valuation basis, it’s hard to argue that any SoundHound — at a price-to-next-12-months sales ratio of more than 50 — is anything but overvalued at the moment. But it’s also clear that careful valuation metrics are not something the markets are overly concerned about right now.

Ultimately this will get resolved one way or the other by financial results, but we won’t get another earnings update on the company until March, meaning online rhetoricians won’t have to incorporate any fresh facts into their arguments for awhile.

For those who are interested in hearing from the horse’s mouth about the prospects for SoundHound AI and learning about the company’s background, we spoke to CEO Keyvan Mohajer back in late October.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.